Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio

PARIS, FRANCE AND SCHLIEREN/ZURICH, SWITZERLAND, 01 JULY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) and Memo Therapeutics AG announced today they have entered into a definitive share purchase agreement under which Ipsen has agreed to acquire all issued and outstanding shares of Memo Therapeutics AG. The anticipated acquisition is focused on potravitug, which is a Phase II clinical-stage antibody against the BK polyomavirus (BKPyV). BK polyomavirus associated nephropathy (BKPyVAN) is a serious and frequent clinical complication in renal transplanted patients that can lead to graft loss and transplant failure. Potravitug was granted fast-track designation from the U.S. Food and Drug Administration (FDA) in May 2023 and orphan drug designation in the European Union in December 2025.